Industry

IMM-BCP-01 neutralized BA.4/.5 and BA.2.12.1 subvariants in pseudovirus testing IMM-BCP-01 currently in Phase 1b clinical testing with topline data expected in 2H 2022 EXTON, Pa.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that their cocktail (IMM-BCP-01) retained activity … [Read more…]

NEW YORK–(BUSINESS WIRE)–Kallyope, Inc., a leading biotechnology company focused on identifying and developing therapeutics involving the gut-brain axis, today announced the promotion of Shirly Pinto, Ph.D., to Chief Scientific Officer and the appointments of Jiajun Liu, Ph.D., as Vice President and Head of Biometrics and Michael Crutchlow, M.D., as Vice President and Head of Translational … [Read more…]

BeiGene and InnoRNA will jointly research a number of mRNA-LNP programs, and BeiGene will hold exclusive global development and commercialization rights for the product candidates from the programs BeiGene will also gain a non-exclusive license to InnoRNA’s proprietary LNP Technology to support internal discovery efforts CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING–(BUSINESS WIRE)–$BGNE #BeiGene–BeiGene (NASDAQ: … [Read more…]

ETTLINGEN, Germany–(BUSINESS WIRE)–$BRKR #BRKR–Bruker Corporation (Nasdaq: BRKR) today has launched PhenoRisk PACS™ RuO, a research-use-only NMR test for molecular phenomics research on ‘Long COVID’ patients’ blood samples, using a multiplexed combination of biomarkers discovered at the Australian National Phenome Center (ANPC) at Murdoch University, under Director Jeremy Nicholson. The PhenoRisk PACS™ RuO test is promising … [Read more…]

Strategic alliance significantly expands ongoing multi-year collaboration by granting Turnstone broader access and enhanced benefits at Moffitt IND approval received for a Moffitt-sponsored Phase 1 study of TIDAL-01 in melanoma NEW YORK & TAMPA, Fla.–(BUSINESS WIRE)–#TIL–Turnstone Biologics Corp., a clinical-stage biotechnology company developing next-generation immunotherapies to treat and cure solid tumors, and Moffitt Cancer Center … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Zolpidem (CAS 82626-48-0) Global Market Research Report 2022” report has been added to ResearchAndMarkets.com’s offering. This global report is a result of industry experts’ diligent work on researching the world market of Zolpidem. The report helps to build up a clear view of the market trends and development, identify major players in the … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Tioclomarol (CAS 22619-35-8) Global Market Research Report 2022” report has been added to ResearchAndMarkets.com’s offering. This global report is a result of industry experts’ diligent work on researching the world market of Tioclomarol. The report helps to build up a clear view of the market trends and development, identify major players in the … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Norfloxacin (CAS 70458-96-7) Global Market Research Report 2022” report has been added to ResearchAndMarkets.com’s offering. This global report is a result of industry experts’ diligent work on researching the world market of Norfloxacin. The report helps to build up a clear view of the market trends and development, identify major players in the … [Read more…]

Dutch hospital drives AI initiatives on a modern analytics and data lakehouse to support data-driven decision making and improve patient care AMSTERDAM–(BUSINESS WIRE)–Hewlett Packard Enterprise (NYSE: HPE) today announced that Catharina Hospital, the largest hospital in the Netherlands’ Eindhoven region, providing care for over 150,000 patients, has selected the HPE Ezmeral software portfolio to build … [Read more…]

LAUSANNE, Switzerland–(BUSINESS WIRE)–Gnubiotics Sciences, a biotech company pioneering the discovery and development of immunomodulatory glycopeptides, today announced that the Swiss Innovation Agency (Innosuisse) will support a research collaboration with the University Hospital Zürich to accelerate the development of Gnubiotics’ GLAAD technology in a range of solid tumors. The total project cost of CHF 1.4 million … [Read more…]